OBJECTIVES: Contrast-induced acute kidney injury (CI-AKI) is a well-known serious complication of percutaneous coronary intervention (PCI) and may cause increased morbidity and mortality. We aim to identify the predictive value of Global Registry for Acute Coronary Events (GRACE) risk scores for CI-AKI in patients with ST-segment elevation myocardial infarction (STEMI) before primary PCI, allowing pre-procedural decisions regarding prevention therapy for CI-AKI. METHODS: We enrolled 251 consecutive patients with STEMI undergoing primary PCI. Receiver operating characteristic curves were used to identify the optimal sensitivity for the observed range of GRACE risk scores. CI-AKI was defined as any of the following: absolute increase in serum creatinine (SCr) of ≥ 0.3 or ≥ 0.5 mg/dL within 48-72 h after contrast exposure, or a percentage increase in SCr level of ≥ 50 %. RESULTS: Forty-three patients (17.1 %) developed CI-AKI0.3, 22 (8.8 %) CI-AKI0.5, and 19 (7.6 %) CI-AKI50. The GRACE quartiles were as follows: Q1 (<136), Q2 (136-159), Q3 (159-180), and Q4 (>180). Patients with high GRACE risk scores had higher risk for CI-AKI0.3, 0.5, and 50 (6.6, 6.6, 23.4, 31.7 %, respectively, p < 0.001; 1.6, 1.6, 9.4, 22.2 %, respectively, p < 0.001; and 3.3, 3.2, 9.4, 14.3 %, respectively, p = 0.009). ROC showed that a GRACE risk score >160 was a fair discriminator for CI-AKI0.3, 0.5, and 50 (C statistic = 0.723, 0.788, 0.668, respectively). After adjusting for potential confounding predictors, GRACE risk score >160 remained significantly associated with CI-AKI0.3 or 0.5 (OR 3.84; 95 % CI 1.61-9.17; p = 0.002, or OR 5.54; 95 % CI 1.42-21.66; p = 0.014), and high-sensitivity C-reactive protein (Hs-CRP) >15.5 mg/L was a highly significant predictor of CI-AKI0.3, 0.5, and CI-AKI50. CONCLUSIONS: GRACE risk score (>160) and post-procedural Hs-CRP >15.5 mg/L are independent and significant predictors of CI-AKI in patients with STEMI before primary PCI.
OBJECTIVES: Contrast-induced acute kidney injury (CI-AKI) is a well-known serious complication of percutaneous coronary intervention (PCI) and may cause increased morbidity and mortality. We aim to identify the predictive value of Global Registry for Acute Coronary Events (GRACE) risk scores for CI-AKI in patients with ST-segment elevation myocardial infarction (STEMI) before primary PCI, allowing pre-procedural decisions regarding prevention therapy for CI-AKI. METHODS: We enrolled 251 consecutive patients with STEMI undergoing primary PCI. Receiver operating characteristic curves were used to identify the optimal sensitivity for the observed range of GRACE risk scores. CI-AKI was defined as any of the following: absolute increase in serum creatinine (SCr) of ≥ 0.3 or ≥ 0.5 mg/dL within 48-72 h after contrast exposure, or a percentage increase in SCr level of ≥ 50 %. RESULTS: Forty-three patients (17.1 %) developed CI-AKI0.3, 22 (8.8 %) CI-AKI0.5, and 19 (7.6 %) CI-AKI50. The GRACE quartiles were as follows: Q1 (<136), Q2 (136-159), Q3 (159-180), and Q4 (>180). Patients with high GRACE risk scores had higher risk for CI-AKI0.3, 0.5, and 50 (6.6, 6.6, 23.4, 31.7 %, respectively, p < 0.001; 1.6, 1.6, 9.4, 22.2 %, respectively, p < 0.001; and 3.3, 3.2, 9.4, 14.3 %, respectively, p = 0.009). ROC showed that a GRACE risk score >160 was a fair discriminator for CI-AKI0.3, 0.5, and 50 (C statistic = 0.723, 0.788, 0.668, respectively). After adjusting for potential confounding predictors, GRACE risk score >160 remained significantly associated with CI-AKI0.3 or 0.5 (OR 3.84; 95 % CI 1.61-9.17; p = 0.002, or OR 5.54; 95 % CI 1.42-21.66; p = 0.014), and high-sensitivity C-reactive protein (Hs-CRP) >15.5 mg/L was a highly significant predictor of CI-AKI0.3, 0.5, and CI-AKI50. CONCLUSIONS: GRACE risk score (>160) and post-procedural Hs-CRP >15.5 mg/L are independent and significant predictors of CI-AKI in patients with STEMI before primary PCI.
Authors: Amir Halkin; Mandeep Singh; Eugenia Nikolsky; Cindy L Grines; James E Tcheng; Eulogio Garcia; David A Cox; Mark Turco; Thomas D Stuckey; Yingo Na; Alexandra J Lansky; Bernard J Gersh; William W O'Neill; Roxana Mehran; Gregg W Stone Journal: J Am Coll Cardiol Date: 2005-05-03 Impact factor: 24.094
Authors: Jordan L Rosenstock; Emmanuelle Gilles; Ari B Geller; Georgia Panagopoulos; Staicy Mathew; Deepa Malieckal; Maria V DeVita; Michael F Michelis Journal: Int Urol Nephrol Date: 2010-07-04 Impact factor: 2.370
Authors: Giuseppe Patti; Elisabetta Ricottini; Annunziata Nusca; Giuseppe Colonna; Vincenzo Pasceri; Andrea D'Ambrosio; Antonio Montinaro; Germano Di Sciascio Journal: Am J Cardiol Date: 2011-04-27 Impact factor: 2.778
Authors: Giuseppe De Luca; Harry Suryapranata; Arnoud W J van 't Hof; Menko-Jan de Boer; Jan C A Hoorntje; Jan-Henk E Dambrink; A T Marcel Gosselink; Jan Paul Ottervanger; Felix Zijlstra Journal: Circulation Date: 2004-05-24 Impact factor: 29.690
Authors: Jassim Al Suwaidi; Donal N Reddan; Kathryn Williams; Karen S Pieper; Robert A Harrington; Robert M Califf; Christopher B Granger; E Magnus Ohman; David R Holmes Journal: Circulation Date: 2002-08-20 Impact factor: 29.690
Authors: Antonio Maria Leone; Alberto Ranieri De Caterina; Alessandro Sciahbasi; Andrea Aurelio; Eloisa Basile; Italo Porto; Carlo Trani; Francesco Burzotta; Giampaolo Niccoli; Rocco Mongiardo; Mario Attilio Mazzari; Antonino Buffon; Nicola Panocchia; Enrico Romagnoli; Ernesto Lioy; Antonio Giuseppe Rebuzzi; Filippo Crea Journal: EuroIntervention Date: 2012-11-22 Impact factor: 6.534